Related Experiment Video
Updated: Sep 15, 2025

06:23
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.7K
Visual Memory Performance Correlates with Alzheimer's Disease Biomarkers in Cognitively Normal Individuals.
Medrxiv : the Preprint Server for Health Sciences
|July 16, 2025
Summary
Visual memory, assessed by the Rey Complex Figure Test (RCFT), is strongly linked to Alzheimer's disease biomarkers. This finding highlights RCFT's potential for early detection of Alzheimer's pathology in at-risk individuals.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Biomarker Research
Background:
- Alzheimer's disease (AD) pathology develops silently for years before clinical symptoms.
- Early identification of individuals at high risk for AD is crucial for better outcomes.
Purpose of the Study:
- To identify cognitive factors related to early Alzheimer's disease pathology.
- To explore the relationship between cognitive performance and established AD biomarkers.
Main Methods:
- Exploratory factor analysis (EFA) was performed on neuropsychological test data from 1,697 healthy adults.
- Factor scores were used as predictors for structural MRI, functional connectivity, and cerebrospinal fluid (CSF) biomarkers.
Main Results:
- EFA identified five latent cognitive factors, including Verbal Memory (Factor 1) and Visual Memory (Factor 2).
- Visual Memory (Factor 2) showed positive correlations with hippocampal volume and posterior salience network connectivity, and a negative correlation with CSF tau.
- Verbal Memory (Factor 1) correlated with hippocampal volume but not with network connectivity or CSF biomarkers.
Conclusions:
- Visual memory performance is significantly associated with Alzheimer's disease biomarkers.
- The Rey Complex Figure Test (RCFT), a measure of visual memory, may be valuable for assessing and monitoring individuals in the earliest stages of AD pathology.
Related Concept Videos
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
Visual Agnosia
310
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round...
310

